Kelly Hallowell

An infographic comparing Truvada and Descovy for HIV PrEP. Both have good efficacy and safety profiles with adverse effects resolving after cessation. Truvada however is studied in more patient populations. Link to the full graphic with hyperlinks for citations here: https://tinyurl.com/4uppwp2s

08.10.2025 17:58 — 👍 4    🔁 2    💬 0    📌 0

I've been working on a quality improvement project teaching internal medicine residents about HIV PrEP prescribing. A sneak peak at one of many infographics I've made so far using the skills I learned from the ID Digital Institute @febrilepodcast.com! #IDSky

08.10.2025 17:58 — 👍 4    🔁 2    💬 2    📌 0

Exciting to see guidelines with a simplification of classifications as well as discussion of the importance of both patient and local resistance patterns!

18.07.2025 18:45 — 👍 2    🔁 0    💬 0    📌 0

Gilead Expands Global Access to Lenacapavir With New HIV Prevention Partnership Gilead Sciences has partnered with the Global Fund to supply up to 2 million doses of its long-acting HIV prevention drug, lenacapavir, to low and lower-middle income countries.

Perhaps a small piece of hopeful news? There is no benefit to a highly effective drugs if we can't get it to the people who need it.

11.07.2025 00:03 — 👍 0    🔁 0    💬 0    📌 0

New to this space! I'm an adult infectious diseases fellow interested in STIs and medical education. Here to learn all your clinical pearls and maybe a share a few of my own.

30.05.2025 18:49 — 👍 1    🔁 0    💬 0    📌 0